Minoxidil and finasteride remain standard FDA-approved treatments for androgenetic alopecia, while off-label and emerging therapies offer evolving management options.
This systematic review outlines the evolving landscape of FDA-approved, off-label, and emerging therapies for androgenetic alopecia.
Absolute Event Rate: 0% vs 0%
Androgenetic alopecia (AGA) is a common, progressive form of nonscarring hair loss, affecting both men and women. Its pathogenesis is largely driven by androgenic factors, including elevated dihydrotestosterone (DHT), leading to follicular miniaturization. While FDA-approved treatments like minoxidil and finasteride are standard, off-label therapies and emerging treatments continue to evolve. This systematic review examines the current and emerging treatment landscape for AGA, focusing on various topical, oral, injectable, and non-pharmacological interventions. .
Bourne et al. (Sun,) reported a other. Minoxidil and finasteride remain standard FDA-approved treatments for androgenetic alopecia, while off-label and emerging therapies offer evolving management options.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: